Condition
Moderate to Severe Plaque Psoriasis clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Moderate to Severe Plaque Psoriasis clinical trials that are recruiting, at sites in 7 countries (most in China (4), South Korea (1), Canada (1)). 1 was first registered in the last 30 days. By phase: Phase 2 (1), Phase 3 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 1New in 30 days
- 7Countries
Newest Moderate to Severe Plaque Psoriasis clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| HS-20137: a treatment option for adults with moderate-to-severe plaque psoriasis | Phase 2 | Beijing, Beijng | Recruiting | Oct 19, 2026 |
| WD-890 in adults with moderate to severe plaque psoriasis | Phase 3 | Nanjing, Jiangsu | Recruiting | Jun 29, 2026 |
| TYK2 inhibitor for adults with moderate to severe plaque psoriasis | — | Shanghai | Recruiting | Nov 18, 2025 |
| Assessing Bimekizumab Levels in Breast Milk of Nursing Mothers | Phase 1 | Santa Monica, California and 13 other locations | Recruiting | Mar 21, 2025 |
| Evaluating the effects of vunakizumab on moderate-to-severe plaque psoriasis | — | Shenyang, Liaoning | Recruiting | Nov 20, 2024 |
| Evaluating the safety and effectiveness of Sotyktu for plaque psoriasis in Korea | — | Seoul and 1 other locations | Recruiting | Feb 14, 2024 |
All recruiting trials (6)
-
HS-20137: a treatment option for adults with moderate-to-severe plaque psoriasis
A phase 2 open-label study tests HS-20137 given as 200 mg at weeks 0, 4 and 8 to see if it is safe and helps patients with moderate-to-severe plaque psoriasis.
-
WD-890 in adults with moderate to severe plaque psoriasis
This study tests whether WD-890 tablets work better than a placebo for adults with moderate to severe plaque psoriasis.
-
TYK2 inhibitor for adults with moderate to severe plaque psoriasis
This will test whether a TYK2 inhibitor taken for 12 weeks helps adults with moderate to severe plaque psoriasis improve their skin and symptoms.
-
Assessing Bimekizumab Levels in Breast Milk of Nursing Mothers
This study tests how much of the medication bimekizumab is found in the breast milk of mothers who have been using it for at least 12 weeks after giving birth to see if it's safe for their babies.
-
Evaluating the effects of vunakizumab on moderate-to-severe plaque psoriasis
This study is testing if a new medication called vunakizumab can help people with moderate-to-severe plaque psoriasis feel better and improve their quality of life over a year.
-
Evaluating the safety and effectiveness of Sotyktu for plaque psoriasis in Korea
This study is testing if a new medication called Sotyktu is safe and effective for adults in Korea with moderate-to-severe plaque psoriasis who need treatment.
Related topics
Quick answers
How many Moderate to Severe Plaque Psoriasis clinical trials are recruiting right now?
6, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 7 countries. The most sites are in China (4 trials), South Korea (1 trial), Canada (1 trial), Germany (1 trial), Spain (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 3: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.